Related Experiment Videos
Combined modality therapy in Stage III and Stage IIIE diffuse large cell lymphomas
Cancer
|April 1, 1984
Summary
This study on diffuse large cell lymphoma found that combined CHOP-Bleo chemotherapy and radiotherapy achieved a 64% 5-year survival rate. Complete remission patients showed significantly better long-term survival and disease-free rates.
Area of Science:
- Oncology
- Hematology
- Clinical Medicine
Background:
- Diffuse large cell lymphoma (DLCL) is an aggressive non-Hodgkin lymphoma.
- Treatment advancements are crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of combined modality therapy for Stage III and IIIE DLCL.
- To identify prognostic factors influencing survival in DLCL patients.
Main Methods:
- 47 patients with Stage III/IIIE DLCL received CHOP-Bleo chemotherapy and limited-field radiotherapy.
- Survival and disease-free survival rates were analyzed.
- Prognostic factors including age, B symptoms, and extranodal involvement were assessed.
Main Results:
- Overall 5-year survival was 64%, with 53% disease-free survival.
- Complete remission was achieved in 29 patients, with 92% alive and 87% disease-free at 5 years.
- Mediastinal and extensive abdominal involvement correlated with poorer response and survival.
Conclusions:
- Combined modality therapy offers significant survival benefits for advanced DLCL.
- Mediastinal and extensive abdominal involvement are negative prognostic indicators.
- Achieving complete remission is critical for long-term disease control.